Vallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference
Vallon Pharmaceuticals (NASDAQ: VLON) will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vallon Pharmaceuticals (NASDAQ: VLON) will present at the H.C. Wainwright 7th Annual Israel Virtual Conference on November 15, 2021, at 8:30 am ET. David Baker, President & CEO, will lead the presentation, which is part of Vallon's commitment to developing novel drugs aimed at preventing abuse in the treatment of CNS disorders. Following the presentation, management will participate in virtual one-on-one meetings with qualified investors. The event will be archived for 90 days on the company's website.
Details
News Market Reaction – VLON
The recorded move for VLON in the trading session of this news was -9.62%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Live video webcast presentation on Monday, November 15th at 8:30 am ET
PHILADELPHIA, PA, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today announced that David Baker, President & Chief Executive Officer will present at the H.C. Wainwright 7th Annual Israel Virtual Conference on Monday, November 15, 2021 at 8:30 am ET.
In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
The video webcast presentation will be accessible on the conference website and on the Events page of the Investors section of the Company’s website (www.vallon-pharma.com) and will be archived for 90 days following the event.
About Vallon Pharmaceuticals, Inc.
Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with CNS disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.
For more information about the company, please visit www.vallon-pharma.com or connect with us on LinkedIn or Twitter.
References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Vallon is not responsible for the contents of third-party websites.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
vallon@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.